Downstream Process Intensification with Novel Chromatography Resins for Enhanced Monoclonal Antibody Purification

Register & watch

Wednesday, June 24, 2020
11:00 - 11:45 EST

In this presentation, we will demonstrate an integrated mAbs downstream purification process to enable significant throughput improvement while removing of critical impurities.

The process approach includes (1) pre-absorption filtration technology and (2) buffer additives. Through use of pre-absorption filtration technology, in combination with PROchievA protein A affinity resin, that possess high dynamic binding capacities of greater than 60 g/L, we have obtained antibodies with increased purity, while reducing overall process time.

Furthermore, by using select additives during process chromatography, we demonstrate this process can be 'fine tuned' to enhance target antibody selectivity by removing host cell protein impurities and aggregates. When used in conjunction, these technologies represent a highly efficient process to obtain monoclonal antibodies for use as therapeutics.

Register & watch

Presented by:

Jonathan Fura

Jonathan is Manager, Research & Development at Avantor. In his current role, Jonathan focuses on developing technologies that are utilised to advance the development and manufacturing of antibody-based biopharmaceuticals and diagnostics. Jonathan holds a Ph.D. in chemistry with a focus on developing immunomodulation therapeutic strategies.

Jungmin Oh

Jungmin is Manager, New Product Development at Avantor. In her current role, Jungmin leads product and process development projects with multiple biopharmaceutical industry partners, including customised product development for cell and gene therapy customers. She holds a MS and Ph.D. in chemical engineering, specialising in the optimisation of a continuous chromatography system.

Joshua Sumoski

Joshua is an Innovation Scientist at Avantor. In his current role, Joshua focuses on downstream purification process development and chromatography product support. He has over 15 years of experience within the biotech/pharma industry in both process development and manufacturing.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.